A CALCIUM and CALMODULIN-dependent cyclic nucleotide phosphodiesterase subfamily. The three members of this family are referred to as type 1A, type 1B, and type 1C and are each product of a distinct gene. In addition, multiple enzyme variants of each subtype can be produced due to multiple alternative mRNA splicing. Although the type 1 enzymes are classified as 3',5'-cyclic-AMP phosphodiesterases (EC 3.1.4.17), some members of this class have additional specificity for CYCLIC GMP.
Enzymes that catalyze the hydrolysis of CYCLIC AMP to form adenosine 5'-phosphate. The enzymes are widely distributed in animal tissue and control the level of intracellular cyclic AMP. Many specific enzymes classified under this heading demonstrate additional spcificity for 3',5'-cyclic IMP and CYCLIC GMP.
A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes.
A cyclic nucleotide phosphodiesterase subfamily that is inhibited by the binding of CYCLIC GMP to an allosteric domain found on the enzyme and through phosphorylation by regulatory kinases such as PROTEIN KINASE A and PROTEIN KINASE B. The two members of this family are referred to as type 3A, and type 3B, and are each product of a distinct gene. In addition multiple enzyme variants of each subtype can be produced due to multiple alternative mRNA splicing.
A cyclic nucleotide phosphodiesterase subfamily that is activated by the binding of CYCLIC GMP to an allosteric domain found on the enzyme. Multiple enzyme variants of this subtype can be produced due to multiple alternative mRNA splicing. The subfamily is expressed in a broad variety of tissues and may play a role in mediating cross-talk between CYCLIC GMP and CYCLIC CMP pathways. Although the type 2 enzymes are classified as 3',5'-cyclic-AMP phosphodiesterases (EC 3.1.4.17), members of this class have additional specificity for CYCLIC GMP.
A class of enzymes that catalyze the hydrolysis of one of the two ester bonds in a phosphodiester compound. EC 3.1.4.
Nucleoside-2',3'-cyclic phosphate nucleotidohydrolase. Enzymes that catalyze the hydrolysis of the 2'- or 3'- phosphate bonds of 2',3'-cyclic nucleotides. Also hydrolyzes nucleoside monophosphates. Includes EC 3.1.4.16 and EC 3.1.4.37. EC 3.1.4.-.
Cyclic nucleotides are a class of molecules that contain a cyclic phosphate group and a nitrogenous base, and play important roles in cellular signaling pathways.
Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.
Enzymes that catalyze the hydrolysis of cyclic GMP to yield guanosine-5'-phosphate.
A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC GMP. It is found predominantly in vascular tissue and plays an important role in regulating VASCULAR SMOOTH MUSCLE contraction.
Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed)
A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC AMP. Several isoforms of the enzyme type exist, each with its own tissue localization. The isoforms are encoded by at least two genes and are a product of multiple alternative splicing of their mRNAs.
An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH.
A phosphodiesterase 4 inhibitor with antidepressant properties.
A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
Purinones are a class of organic compounds derived from purines, which are important for the metabolism of nucleic acids and have potential therapeutic applications in the medical field.
Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A heat-stable, low-molecular-weight activator protein found mainly in the brain and heart. The binding of calcium ions to this protein allows this protein to bind to cyclic nucleotide phosphodiesterases and to adenyl cyclase with subsequent activation. Thereby this protein modulates cyclic AMP and cyclic GMP levels.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
The rate dynamics in chemical or physical systems.
A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC GMP. It is found predominantly in the outer segment PHOTORECEPTOR CELLS of the RETINA. It is comprised of two catalytic subunits, referred to as alpha and beta, that form a dimer. In addition two regulatory subunits, referred to as gamma and delta, modulate the activity and localization of the enzyme.
The monomeric units from which DNA or RNA polymers are constructed. They consist of a purine or pyrimidine base, a pentose sugar, and a phosphate group. (From King & Stansfield, A Dictionary of Genetics, 4th ed)
Compounds that specifically inhibit PHOSPHODIESTERASE 3.
Compounds that specifically inhibit PHOSPHODIESTERASE 4.
Inhibitor of phosphodiesterases.
N-(1-Oxobutyl)-cyclic 3',5'-(hydrogen phosphate)-2'-butanoate guanosine. A derivative of cyclic GMP. It has a higher resistance to extracellular and intracellular phosphodiesterase than cyclic GMP.
A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP.
A phosphoric diester hydrolase that removes 5'-nucleotides from the 3'-hydroxy termini of 3'-hydroxy-terminated OLIGONUCLEOTIDES. It has low activity towards POLYNUCLEOTIDES and the presence of 3'-phosphate terminus on the substrate may inhibit hydrolysis.
A subgroup of cyclic nucleotide-regulated ION CHANNELS within the superfamily of pore-loop cation channels. They are expressed in OLFACTORY NERVE cilia and in PHOTORECEPTOR CELLS and some PLANTS.
Enzymes that catalyze the cleavage of a phosphorus-oxygen bond by means other than hydrolysis or oxidation. EC 4.6.
A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone.
A cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed)
A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed)
Adenine nucleotides are molecules that contain the nitrogenous base adenine and are involved in various biological processes, including energy metabolism and DNA synthesis.
A group of enzymes that are dependent on CYCLIC AMP and catalyze the phosphorylation of SERINE or THREONINE residues on proteins. Included under this category are two cyclic-AMP-dependent protein kinase subtypes, each of which is defined by its subunit composition.
A group of cyclic GMP-dependent enzymes that catalyze the phosphorylation of SERINE or THREONINE residues of proteins.
An enzyme of the lyase class that catalyzes the formation of CYCLIC AMP and pyrophosphate from ATP. EC 4.6.1.1.
Systems in which an intracellular signal is generated in response to an intercellular primary messenger such as a hormone or neurotransmitter. They are intermediate signals in cellular processes such as metabolism, secretion, contraction, phototransduction, and cell growth. Examples of second messenger systems are the adenyl cyclase-cyclic AMP system, the phosphatidylinositol diphosphate-inositol triphosphate system, and the cyclic GMP system.
An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.
Inosine cyclic 3',5'-(hydrogen phosphate). An inosine nucleotide which acts as a mild inhibitor of the hydrolysis of cyclic AMP and cyclic GMP and as an inhibitor of cat heart cyclic AMP phosphodiesterase.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland.
An enzyme that catalyzes the conversion of GTP to 3',5'-cyclic GMP and pyrophosphate. It also acts on ITP and dGTP. (From Enzyme Nomenclature, 1992) EC 4.6.1.2.
The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells.
A single nucleotide variation in a genetic sequence that occurs at appreciable frequency in the population.
Compounds that specifically inhibit PHOSPHODIESTERASE 5.
A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Guanine nucleotides are a type of nucleotide that contains the nitrogenous base guanine and play important roles in various biological processes, including DNA and RNA synthesis, energy metabolism, and signal transduction.
Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor.
The process of cleaving a chemical compound by the addition of a molecule of water.
Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
Purine bases found in body tissues and fluids and in some plants.
The parts of a macromolecule that directly participate in its specific combination with another molecule.
The region of an enzyme that interacts with its substrate to cause the enzymatic reaction.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A group of indole-indoline dimers which are ALKALOIDS obtained from the VINCA genus of plants. They inhibit polymerization of TUBULIN into MICROTUBULES thus blocking spindle formation and arresting cells in METAPHASE. They are some of the most useful ANTINEOPLASTIC AGENTS.
Cyclic P-oxides are a class of cyclic ethers that contain a ring of atoms with an oxygen atom bonded to two adjacent carbon atoms.
Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme.
A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts.
The degree of similarity between sequences of amino acids. This information is useful for the analyzing genetic relatedness of proteins and species.

Cyclic Nucleotide Phosphodiesterases, Type 1 (PDE1) are a family of enzymes that break down cyclic nucleotides, such as cyclic AMP (cAMP) and cyclic GMP (cGMP), into their corresponding monophosphates. These enzymes play a crucial role in regulating various cellular processes, including muscle contraction, neurotransmission, and immune function. In the medical field, PDE1 inhibitors are being investigated as potential treatments for a variety of conditions, including heart failure, erectile dysfunction, and neurological disorders. These inhibitors work by increasing the levels of cAMP or cGMP in the cell, leading to the activation of downstream signaling pathways that promote beneficial effects. However, PDE1 inhibitors can also have side effects, such as headache, flushing, and gastrointestinal symptoms, and their use may be limited by potential drug interactions and other safety concerns. Therefore, further research is needed to fully understand the therapeutic potential and safety profile of PDE1 inhibitors in the medical field.

3',5'-Cyclic-AMP phosphodiesterases (PDEs) are a family of enzymes that play a crucial role in regulating the levels of cyclic AMP (cAMP) in the body. cAMP is a signaling molecule that is involved in a wide range of cellular processes, including cell growth, differentiation, and metabolism. PDEs are responsible for breaking down cAMP into inactive products, thereby regulating the levels of this signaling molecule in the body. There are 11 different subtypes of PDEs, each with its own specific substrate specificity and tissue distribution. In the medical field, PDEs are of particular interest because they are involved in the regulation of many different physiological processes, including the cardiovascular system, the nervous system, and the immune system. In addition, PDEs are the targets of many drugs, including some used to treat conditions such as erectile dysfunction, asthma, and heart failure.

Cyclic Nucleotide Phosphodiesterases, Type 4 (PDE4) are a family of enzymes that break down cyclic AMP (cAMP) and cyclic GMP (cGMP) in the body. These enzymes play a crucial role in regulating various cellular processes, including inflammation, immune response, and muscle contraction. PDE4 enzymes are found in a variety of tissues, including the lungs, heart, and immune cells. They are also present in the brain, where they play a role in regulating mood and cognition. In the medical field, PDE4 inhibitors are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), psoriasis, and depression. These drugs work by inhibiting the activity of PDE4 enzymes, leading to an accumulation of cAMP and cGMP in the cell. This, in turn, can result in a range of therapeutic effects, depending on the tissue and condition being treated.

Cyclic Nucleotide Phosphodiesterases, Type 3 (PDE3) are a family of enzymes that play a crucial role in regulating the levels of cyclic AMP (cAMP) and cyclic GMP (cGMP) in the body. These enzymes are found in a variety of tissues, including the heart, blood vessels, and immune system. PDE3 enzymes are responsible for breaking down cAMP and cGMP, which are important signaling molecules that regulate a wide range of cellular processes, including muscle contraction, blood vessel dilation, and immune cell activation. By breaking down these molecules, PDE3 enzymes help to maintain the appropriate balance of cAMP and cGMP in the body. In the medical field, PDE3 inhibitors are often used to treat conditions such as heart failure, high blood pressure, and asthma. These drugs work by blocking the activity of PDE3 enzymes, which leads to increased levels of cAMP and cGMP in the body. This, in turn, can help to improve blood flow, relax blood vessels, and reduce inflammation, among other effects. Overall, PDE3 enzymes play a critical role in regulating the levels of cAMP and cGMP in the body, and PDE3 inhibitors are an important class of drugs used to treat a variety of medical conditions.

Cyclic Nucleotide Phosphodiesterases, Type 2 (PDE2) are a family of enzymes that break down cyclic nucleotides, such as cyclic AMP (cAMP) and cyclic GMP (cGMP), into their corresponding monophosphates. These enzymes play a crucial role in regulating various cellular processes, including signal transduction, gene expression, and metabolism. In the medical field, PDE2 inhibitors are being investigated as potential therapeutic agents for a variety of diseases, including Parkinson's disease, Alzheimer's disease, and schizophrenia. These inhibitors work by increasing the levels of cAMP and cGMP in the cell, which can lead to the activation of downstream signaling pathways and the modulation of various cellular processes. PDE2 inhibitors have also been shown to have anti-inflammatory and anti-cancer effects, and are being studied as potential treatments for inflammatory diseases and cancer. However, more research is needed to fully understand the therapeutic potential of PDE2 inhibitors and to develop safe and effective drugs for these indications.

Phosphoric diester hydrolases are a group of enzymes that catalyze the hydrolysis of phosphoric diesters, which are esters of phosphoric acid. These enzymes are involved in a variety of biological processes, including the breakdown of nucleic acids, the metabolism of lipids, and the regulation of signaling pathways. In the medical field, phosphoric diester hydrolases are important for the proper functioning of the body. For example, they are involved in the breakdown of nucleic acids, which are the building blocks of DNA and RNA. This process is essential for the replication and repair of DNA, as well as the production of proteins from genetic information. Phosphoric diester hydrolases are also involved in the metabolism of lipids, which are a type of fat that is stored in the body. These enzymes help to break down lipids into smaller molecules that can be used for energy or stored for later use. In addition, phosphoric diester hydrolases play a role in the regulation of signaling pathways, which are the communication networks that allow cells to respond to changes in their environment. These enzymes help to control the activity of signaling molecules, which can affect a wide range of cellular processes, including cell growth, differentiation, and death. Overall, phosphoric diester hydrolases are important enzymes that play a variety of roles in the body. They are involved in the breakdown of nucleic acids, the metabolism of lipids, and the regulation of signaling pathways, and are essential for the proper functioning of the body.

2',3'-Cyclic-Nucleotide Phosphodiesterases (CNP) are a family of enzymes that play a crucial role in regulating the levels of cyclic nucleotides, such as cyclic AMP (cAMP) and cyclic GMP (cGMP), in the body. These enzymes are responsible for breaking down cyclic nucleotides into their corresponding monophosphates, which are then further degraded into inorganic phosphate and ribose or guanine. Cyclic nucleotides are important signaling molecules that regulate a wide range of cellular processes, including gene expression, cell growth and differentiation, and ion channel activity. CNP enzymes are involved in the regulation of these processes by controlling the levels of cyclic nucleotides in the cell. There are several different types of CNP enzymes, including 2',3'-Cyclic-Nucleotide 3'-Phosphodiesterase (CNP), 2',3'-Cyclic-Nucleotide 5'-Phosphodiesterase (CNPB), and 2',3'-Cyclic-Nucleotide 5'-Phosphodiesterase (CNPA). These enzymes are found in a variety of tissues and cells throughout the body, including the brain, heart, and immune system. Abnormalities in the function of CNP enzymes have been linked to a number of diseases and disorders, including hypertension, heart failure, and certain types of cancer. As such, CNP enzymes are an important area of research in the field of medicine, with potential therapeutic applications in the treatment of these conditions.

In the medical field, "Nucleotides, Cyclic" refers to a class of molecules that are composed of a cyclic structure containing a nitrogenous base, a pentose sugar, and a phosphate group. These molecules are important components of DNA and RNA, which are the genetic material of all living organisms. Cyclic nucleotides are a subclass of nucleotides that have a cyclic structure formed by the condensation of the sugar and phosphate groups. They are involved in various cellular signaling pathways and have been implicated in the regulation of a wide range of physiological processes, including blood pressure, heart rate, and immune function. Examples of cyclic nucleotides include cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). These molecules are synthesized from their respective nucleoside triphosphates (ATP and GTP) by the action of enzymes called adenylate cyclase and guanylate cyclase, respectively.

3',5'-Cyclic-GMP Phosphodiesterases (cGMP-PDEs) are a family of enzymes that play a crucial role in regulating the levels of cyclic guanosine monophosphate (cGMP) in the body. cGMP is a second messenger molecule that is involved in a wide range of cellular processes, including smooth muscle relaxation, neurotransmission, and immune cell function. cGMP-PDEs are responsible for breaking down cGMP into guanosine monophosphate (GMP), thereby terminating the signaling effects of cGMP. There are 11 different subtypes of cGMP-PDEs, each with different tissue distribution and substrate specificity. In the medical field, cGMP-PDEs are of particular interest because they are targeted by a class of drugs called phosphodiesterase inhibitors (PDE inhibitors). PDE inhibitors are used to treat a variety of conditions, including erectile dysfunction, pulmonary hypertension, and glaucoma. By inhibiting cGMP-PDEs, PDE inhibitors increase the levels of cGMP in the body, leading to the desired therapeutic effects.

Cyclic Nucleotide Phosphodiesterases, Type 5 (PDE5) are a group of enzymes that break down cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) in the body. These enzymes play a crucial role in regulating various physiological processes, including blood flow, smooth muscle contraction, and neurotransmission. In the context of sexual function, PDE5 inhibitors are a class of drugs that work by blocking the action of PDE5, thereby increasing levels of cGMP in the penis. This leads to improved blood flow to the penis and helps to achieve and maintain an erection during sexual activity. PDE5 inhibitors are commonly used to treat erectile dysfunction (ED) and are also being studied for other conditions, such as pulmonary hypertension and vision loss.

Cyclic GMP (cGMP) is a signaling molecule that plays a crucial role in regulating various physiological processes in the body, including smooth muscle contraction, neurotransmission, and blood pressure regulation. It is synthesized from guanosine triphosphate (GTP) by the enzyme guanylate cyclase and is degraded by the enzyme phosphodiesterase. In the medical field, cGMP is often studied in the context of its role in the regulation of blood vessels and the cardiovascular system. For example, cGMP is involved in the dilation of blood vessels, which helps to lower blood pressure and improve blood flow. It is also involved in the regulation of heart rate and contractility. Abnormal levels of cGMP can lead to a variety of medical conditions, including hypertension, heart failure, and erectile dysfunction. In these cases, medications that either increase or decrease cGMP levels may be used to treat the underlying condition.

Cyclic Nucleotide Phosphodiesterases, Type 7 (PDE7) are a family of enzymes that break down cyclic nucleotides, such as cyclic AMP (cAMP) and cyclic GMP (cGMP), in the body. These enzymes play a crucial role in regulating various cellular processes, including cell growth, differentiation, and apoptosis. In the medical field, PDE7 inhibitors are being studied as potential therapeutic agents for a variety of diseases, including cancer, inflammatory disorders, and neurological disorders. These inhibitors work by blocking the activity of PDE7 enzymes, leading to an accumulation of cyclic nucleotides in the cell and activation of downstream signaling pathways. PDE7 inhibitors have shown promise in preclinical studies for the treatment of various types of cancer, including breast cancer, prostate cancer, and lung cancer. They have also been shown to have anti-inflammatory effects and may have potential as treatments for inflammatory disorders such as psoriasis and rheumatoid arthritis. Additionally, PDE7 inhibitors have been shown to have neuroprotective effects and may have potential as treatments for neurological disorders such as Alzheimer's disease and Parkinson's disease.

Cyclic AMP (cAMP) is a signaling molecule that plays a crucial role in many cellular processes, including metabolism, gene expression, and cell proliferation. It is synthesized from adenosine triphosphate (ATP) by the enzyme adenylyl cyclase, and its levels are regulated by various hormones and neurotransmitters. In the medical field, cAMP is often studied in the context of its role in regulating cellular signaling pathways. For example, cAMP is involved in the regulation of the immune system, where it helps to activate immune cells and promote inflammation. It is also involved in the regulation of the cardiovascular system, where it helps to regulate heart rate and blood pressure. In addition, cAMP is often used as a tool in research to study cellular signaling pathways. For example, it is commonly used to activate or inhibit specific signaling pathways in cells, allowing researchers to study the effects of these pathways on cellular function.

Rolipram is a medication that belongs to a class of drugs called phosphodiesterase type 4 (PDE4) inhibitors. It is primarily used to treat asthma and chronic obstructive pulmonary disease (COPD) by relaxing the muscles in the airways and improving breathing. Rolipram may also be used to treat other conditions, such as psoriasis and inflammatory bowel disease, by reducing inflammation in the body. It is usually taken by mouth in the form of tablets or capsules.

1-Methyl-3-isobutylxanthine, also known as IBMX, is a chemical compound that belongs to the xanthine family. It is a selective inhibitor of the enzyme phosphodiesterase type 4 (PDE4), which is involved in the breakdown of cyclic AMP (cAMP) in cells. In the medical field, IBMX is used as a research tool to study the effects of PDE4 inhibition on various physiological processes, including inflammation, pain, and airway smooth muscle contraction. It has also been investigated as a potential treatment for a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and psoriasis. However, IBMX is not currently approved for use as a therapeutic agent in humans, as it can have significant side effects, including nausea, vomiting, diarrhea, and increased heart rate. Additionally, prolonged use of IBMX can lead to the development of tolerance and dependence.

Purinones are a class of organic compounds that are derived from purine, a nitrogen-containing heterocyclic base found in nucleic acids such as DNA and RNA. Purinones are important in the field of medicine because they are involved in various biological processes, including energy metabolism, cell signaling, and immune function. One of the most well-known purinones is adenosine, which is a signaling molecule that plays a role in regulating blood flow, inflammation, and neurotransmission. Adenosine is also a precursor to ATP, the primary energy currency of cells. Other purinones include hypoxanthine, xanthine, and uric acid, which are involved in the metabolism of purines and the production of uric acid, a waste product that is excreted by the kidneys. High levels of uric acid in the blood can lead to gout, a painful joint condition. Purinones are also used in the development of drugs for a variety of medical conditions, including cancer, cardiovascular disease, and inflammatory disorders. For example, the drug allopurinol is used to lower uric acid levels in people with gout, while the drug caffeine is a purine derivative that is used to stimulate the central nervous system.

In the medical field, isoenzymes refer to different forms of enzymes that have the same chemical structure and catalytic activity, but differ in their amino acid sequence. These differences can arise due to genetic variations or post-translational modifications, such as phosphorylation or glycosylation. Isoenzymes are often used in medical diagnosis and treatment because they can provide information about the function and health of specific organs or tissues. For example, the presence of certain isoenzymes in the blood can indicate liver or kidney disease, while changes in the levels of specific isoenzymes in the brain can be indicative of neurological disorders. In addition, isoenzymes can be used as biomarkers for certain diseases or conditions, and can be targeted for therapeutic intervention. For example, drugs that inhibit specific isoenzymes can be used to treat certain types of cancer or heart disease.

Calmodulin is a small, calcium-binding protein that plays a crucial role in regulating various cellular processes in the body. It is found in all eukaryotic cells and is involved in a wide range of physiological functions, including muscle contraction, neurotransmitter release, and gene expression. Calmodulin is a tetramer, meaning that it is composed of four identical subunits, each of which contains two EF-hand calcium-binding domains. When calcium ions bind to these domains, the structure of calmodulin changes, allowing it to interact with and regulate the activity of various target proteins. In the medical field, calmodulin is often studied in the context of various diseases and disorders, including cardiovascular disease, cancer, and neurological disorders. For example, abnormal levels of calmodulin have been associated with the development of certain types of cancer, and calmodulin inhibitors have been investigated as potential therapeutic agents for treating these diseases. Additionally, calmodulin has been implicated in the pathogenesis of various neurological disorders, including Alzheimer's disease and Parkinson's disease.

In the medical field, an amino acid sequence refers to the linear order of amino acids in a protein molecule. Proteins are made up of chains of amino acids, and the specific sequence of these amino acids determines the protein's structure and function. The amino acid sequence is determined by the genetic code, which is a set of rules that specifies how the sequence of nucleotides in DNA is translated into the sequence of amino acids in a protein. Each amino acid is represented by a three-letter code, and the sequence of these codes is the amino acid sequence of the protein. The amino acid sequence is important because it determines the protein's three-dimensional structure, which in turn determines its function. Small changes in the amino acid sequence can have significant effects on the protein's structure and function, and this can lead to diseases or disorders. For example, mutations in the amino acid sequence of a protein involved in blood clotting can lead to bleeding disorders.

Cyclic Nucleotide Phosphodiesterases, Type 6 (PDE6) are a family of enzymes that are responsible for breaking down cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), in the retina of the eye. These enzymes play a crucial role in regulating the transmission of visual signals from the retina to the brain. PDE6 is a heterodimeric enzyme composed of two subunits, alpha and beta, which are encoded by different genes. The alpha subunit contains the catalytic site of the enzyme, while the beta subunit is involved in the regulation of the enzyme's activity. Mutations in the genes encoding PDE6 can cause a group of inherited eye disorders known as cone-rod dystrophies, which affect the photoreceptor cells in the retina responsible for color vision and night vision. These disorders are characterized by progressive vision loss and can lead to blindness in affected individuals.

In the medical field, nucleotides are the building blocks of nucleic acids, which are the genetic material of cells. Nucleotides are composed of three components: a nitrogenous base, a pentose sugar, and a phosphate group. There are four nitrogenous bases in DNA: adenine (A), thymine (T), cytosine (C), and guanine (G). There are also four nitrogenous bases in RNA: adenine (A), uracil (U), cytosine (C), and guanine (G). The sequence of these nitrogenous bases determines the genetic information encoded in DNA and RNA.

Dibutyryl cyclic guanosine monophosphate (db-cGMP) is a synthetic analog of cyclic guanosine monophosphate (cGMP), a signaling molecule that plays a crucial role in various physiological processes, including smooth muscle relaxation, neurotransmission, and immune cell function. Db-cGMP is a stable, long-lasting form of cGMP that can be used in research to study the effects of cGMP on cellular signaling pathways. It is often used as a tool to investigate the function of cGMP-dependent protein kinases (PKG) and other signaling proteins that are activated by cGMP. In the medical field, db-cGMP has been studied as a potential therapeutic agent for a variety of conditions, including erectile dysfunction, hypertension, and glaucoma. It has also been used in research to investigate the role of cGMP in various diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

Theophylline is a medication that is used to treat a variety of respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. It works by relaxing the muscles in the airways, making it easier to breathe. Theophylline is available in both oral and inhaled forms, and it is usually taken on a regular basis to prevent symptoms from occurring. It is important to note that theophylline can have side effects, including nausea, vomiting, and an irregular heartbeat, and it should only be taken under the supervision of a healthcare provider.

Phosphodiesterase I (PDE1) is an enzyme that breaks down cyclic nucleotides, such as cyclic AMP (cAMP) and cyclic GMP (cGMP), into their corresponding monophosphates. These cyclic nucleotides are important signaling molecules in the body that regulate various cellular processes, including muscle contraction, neurotransmission, and gene expression. PDE1 is primarily found in the brain and smooth muscle tissue, where it plays a role in regulating the levels of cAMP and cGMP. In the brain, PDE1 is involved in the regulation of learning, memory, and mood. In smooth muscle tissue, PDE1 is involved in the regulation of blood pressure and heart rate. Inhibition of PDE1 has been shown to have therapeutic potential in the treatment of various conditions, including hypertension, heart failure, and cognitive disorders. However, the use of PDE1 inhibitors can also have side effects, such as headache, nausea, and dizziness.

Cyclic Nucleotide-Gated Cation Channels (CNGCs) are a family of ion channels that are activated by the binding of cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). These channels are found in a variety of cell types, including photoreceptor cells in the retina, olfactory sensory neurons, and neurons in the brain and spinal cord. CNGCs are responsible for mediating a number of physiological processes, including the transduction of light in the retina, the detection of odorants in the nose, and the regulation of neuronal excitability. They are also involved in a number of diseases, including retinitis pigmentosa, olfactory loss, and certain types of epilepsy. CNGCs are composed of five subunits, each of which contains a pore-forming region and a cyclic nucleotide-binding domain. When cyclic nucleotides bind to the cyclic nucleotide-binding domain, it causes a conformational change in the channel that opens the pore and allows cations to flow through. The flow of cations generates an electrical signal that can be detected by the cell.

Phosphorus-Oxygen Lyases are a group of enzymes that catalyze the transfer of a phosphate group from a donor molecule to an acceptor molecule, with the release of oxygen. These enzymes are involved in various metabolic pathways, including the breakdown of certain amino acids and the synthesis of nucleotides. In the medical field, phosphorus-oxygen lyases are of interest because they play a role in the metabolism of certain drugs and toxins, and may be involved in the development of certain diseases. For example, some phosphorus-oxygen lyases are involved in the metabolism of alcohol, and their activity may be altered in individuals with alcohol use disorder. Additionally, some phosphorus-oxygen lyases are involved in the metabolism of certain drugs, and their activity may be affected by the use of these drugs.

Milrinone is a medication that is used to treat heart failure and to improve blood flow in the body. It is a type of medication called a phosphodiesterase inhibitor, which works by relaxing the muscles in blood vessels and increasing the strength of heart contractions. Milrinone is usually given as an intravenous infusion, and it can be used to treat both acute and chronic heart failure. It is also sometimes used to treat low blood pressure during surgery.

Bucladesine is a medication that is used to treat certain types of cancer, including lung cancer and pancreatic cancer. It works by slowing the growth of cancer cells and preventing them from dividing and multiplying. Bucladesine is usually given as an injection into a vein, and it is typically administered in a hospital setting. It is important to note that bucladesine is not a cure for cancer, but it can help to slow the progression of the disease and improve the quality of life for people who are living with cancer.

Pyrrolidinones are a class of organic compounds that contain a five-membered ring with four carbon atoms and one nitrogen atom. They are commonly used in the medical field as intermediates in the synthesis of various drugs and as active ingredients in some medications. One example of a drug that contains a pyrrolidinone moiety is metformin, which is used to treat type 2 diabetes. Metformin is a biguanide, which is a class of drugs that work by reducing the amount of glucose produced by the liver and improving the body's sensitivity to insulin. Pyrrolidinones are also used as chelating agents, which are compounds that bind to metal ions and help to remove them from the body. One example of a pyrrolidinone chelating agent is dimercaprol, which is used to treat heavy metal poisoning, such as from mercury or lead. In addition to their use in medicine, pyrrolidinones have a wide range of other applications, including as solvents, plasticizers, and corrosion inhibitors.

Adenine nucleotides are a type of nucleotide that contains the nitrogenous base adenine (A) and a sugar-phosphate backbone. They are important molecules in the cell and play a crucial role in various biological processes, including energy metabolism and DNA synthesis. There are three types of adenine nucleotides: adenosine monophosphate (AMP), adenosine diphosphate (ADP), and adenosine triphosphate (ATP). AMP is the simplest form of adenine nucleotide, with only one phosphate group attached to the sugar. ADP has two phosphate groups attached to the sugar, while ATP has three phosphate groups. ATP is often referred to as the "energy currency" of the cell because it stores and releases energy through the transfer of phosphate groups. When ATP is broken down, one of its phosphate groups is released, releasing energy that can be used by the cell for various processes. When ATP is synthesized, energy is required to attach a new phosphate group to the molecule. Adenine nucleotides are involved in many cellular processes, including muscle contraction, nerve impulse transmission, and the synthesis of proteins and nucleic acids. They are also important in the regulation of gene expression and the maintenance of cellular homeostasis.

Cyclic AMP-dependent protein kinases (also known as cAMP-dependent protein kinases or PKA) are a family of enzymes that play a crucial role in regulating various cellular processes in the body. These enzymes are activated by the presence of cyclic AMP (cAMP), a second messenger molecule that is produced in response to various stimuli, such as hormones, neurotransmitters, and growth factors. PKA is a heterotetrameric enzyme composed of two regulatory subunits and two catalytic subunits. The regulatory subunits bind to cAMP and prevent the catalytic subunits from phosphorylating their target proteins. When cAMP levels rise, the regulatory subunits are activated and release the catalytic subunits, allowing them to phosphorylate their target proteins. PKA is involved in a wide range of cellular processes, including metabolism, gene expression, cell proliferation, and differentiation. It phosphorylates various proteins, including enzymes, transcription factors, and ion channels, leading to changes in their activity and function. In the medical field, PKA plays a critical role in various diseases and disorders, including cancer, diabetes, and cardiovascular disease. For example, PKA is involved in the regulation of insulin secretion in pancreatic beta cells, and its dysfunction has been implicated in the development of type 2 diabetes. PKA is also involved in the regulation of blood pressure and heart function, and its dysfunction has been linked to the development of hypertension and heart disease.

Cyclic GMP-dependent protein kinases (PKG) are a family of enzymes that play a crucial role in regulating various cellular processes, including smooth muscle contraction, neurotransmitter release, and gene expression. These enzymes are activated by the second messenger molecule cyclic guanosine monophosphate (cGMP), which is produced in response to various stimuli such as nitric oxide (NO) and other signaling molecules. PKG is a serine/threonine kinase that phosphorylates target proteins on specific amino acid residues, leading to changes in their activity or localization. The activity of PKG is tightly regulated by its subcellular localization, substrate availability, and the concentration of cGMP. In the medical field, PKG is of great interest due to its role in various diseases, including cardiovascular disease, hypertension, and erectile dysfunction. PKG inhibitors have been developed as potential therapeutic agents for these conditions, and ongoing research is exploring the potential of PKG activators as novel treatments for various diseases.

Adenylate cyclase is an enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), a second messenger molecule that plays a crucial role in many cellular signaling pathways. In the medical field, adenylate cyclase is often studied in the context of its role in regulating various physiological processes, including heart rate, blood pressure, and glucose metabolism. It is also involved in the regulation of hormone signaling, particularly in the endocrine system, where hormones such as adrenaline and thyroid hormones bind to specific receptors on the cell surface and activate adenylate cyclase, leading to the production of cAMP and the activation of downstream signaling pathways. Abnormalities in adenylate cyclase activity have been implicated in a number of diseases, including diabetes, hypertension, and certain forms of heart disease. As such, understanding the regulation and function of adenylate cyclase is an important area of research in the medical field.

Papaverine is a medication that is used to treat a variety of medical conditions, including erectile dysfunction, Raynaud's disease, and glaucoma. It is a vasodilator, which means that it helps to widen blood vessels and improve blood flow. Papaverine is usually administered intravenously or intramuscularly, and it can cause side effects such as headache, nausea, and dizziness. It is important to note that papaverine should only be used under the supervision of a healthcare professional.

I'm sorry, but I'm not aware of any medical term or abbreviation called "Cyclic IMP." It's possible that you may have misspelled the term or that it is a term used in a specific medical field or specialty that I am not familiar with. If you could provide more context or information about where you heard or saw this term, I may be able to provide a more accurate answer.

In the medical field, a base sequence refers to the specific order of nucleotides (adenine, thymine, cytosine, and guanine) that make up the genetic material (DNA or RNA) of an organism. The base sequence determines the genetic information encoded within the DNA molecule and ultimately determines the traits and characteristics of an individual. The base sequence can be analyzed using various techniques, such as DNA sequencing, to identify genetic variations or mutations that may be associated with certain diseases or conditions.

Colforsin is a synthetic decapeptide that mimics the action of adenosine, a naturally occurring molecule that plays a role in regulating various physiological processes in the body. It is used in the medical field as a bronchodilator, which means it helps to relax and widen the airways in the lungs, making it easier to breathe. Colforsin is typically administered as an aerosol or nebulizer solution and is used to treat conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. It works by activating adenosine receptors in the lungs, which leads to the release of calcium from the cells lining the airways, causing them to relax and open up.

Guanylate cyclase is an enzyme that plays a crucial role in the regulation of various physiological processes in the body, including blood pressure, smooth muscle contraction, and immune function. It is a membrane-bound protein that catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), a second messenger molecule that regulates the activity of various proteins in the cell. In the cardiovascular system, guanylate cyclase is activated by nitric oxide (NO), a signaling molecule that is released by endothelial cells in response to various stimuli, such as shear stress or the presence of certain hormones. Activation of guanylate cyclase by NO leads to an increase in cGMP levels, which in turn causes relaxation of smooth muscle cells in blood vessels, leading to vasodilation and a decrease in blood pressure. Guanylate cyclase is also involved in the regulation of immune function, as it is activated by various immune cells and cytokines. Activation of guanylate cyclase by immune cells leads to the production of cGMP, which regulates the activity of immune cells and helps to maintain immune homeostasis. In addition, guanylate cyclase is involved in the regulation of various other physiological processes, such as neurotransmission, vision, and hearing. It is a key enzyme in the regulation of these processes and plays a crucial role in maintaining normal physiological function.

Cloning, molecular, in the medical field refers to the process of creating identical copies of a specific DNA sequence or gene. This is achieved through a technique called polymerase chain reaction (PCR), which amplifies a specific DNA sequence to produce multiple copies of it. Molecular cloning is commonly used in medical research to study the function of specific genes, to create genetically modified organisms for therapeutic purposes, and to develop new drugs and treatments. It is also used in forensic science to identify individuals based on their DNA. In the context of human cloning, molecular cloning is used to create identical copies of a specific gene or DNA sequence from one individual and insert it into the genome of another individual. This technique has been used to create transgenic animals, but human cloning is currently illegal in many countries due to ethical concerns.

8-Bromo Cyclic Adenosine Monophosphate (8-Br-cAMP) is a synthetic analog of cyclic adenosine monophosphate (cAMP), a signaling molecule that plays a crucial role in various cellular processes, including cell growth, differentiation, and metabolism. In the medical field, 8-Br-cAMP is used as a tool to study the effects of cAMP on cellular signaling pathways. It is often used in cell culture experiments to increase intracellular cAMP levels and investigate the downstream effects on gene expression, protein synthesis, and cellular behavior. 8-Br-cAMP is also used in some clinical applications, such as the treatment of certain types of cancer. It has been shown to inhibit the growth of some cancer cells by blocking the activity of certain enzymes involved in cell proliferation. However, more research is needed to fully understand the potential therapeutic applications of 8-Br-cAMP in medicine.

Calcium is a chemical element with the symbol Ca and atomic number 20. It is a vital mineral for the human body and is essential for many bodily functions, including bone health, muscle function, nerve transmission, and blood clotting. In the medical field, calcium is often used to diagnose and treat conditions related to calcium deficiency or excess. For example, low levels of calcium in the blood (hypocalcemia) can cause muscle cramps, numbness, and tingling, while high levels (hypercalcemia) can lead to kidney stones, bone loss, and other complications. Calcium supplements are often prescribed to people who are at risk of developing calcium deficiency, such as older adults, vegetarians, and people with certain medical conditions. However, it is important to note that excessive calcium intake can also be harmful, and it is important to follow recommended dosages and consult with a healthcare provider before taking any supplements.

Guanine nucleotides are a type of nucleotide that contains the nitrogenous base guanine. They are important components of DNA and RNA, which are the genetic material of all living organisms. In DNA, guanine nucleotides are paired with cytosine nucleotides to form the base pair G-C, which is one of the four possible base pairs in DNA. In RNA, guanine nucleotides are paired with uracil nucleotides to form the base pair G-U. Guanine nucleotides play a crucial role in the structure and function of DNA and RNA, and are involved in many important biological processes, including gene expression, DNA replication, and protein synthesis.

In the medical field, the term "cattle" refers to large domesticated animals that are raised for their meat, milk, or other products. Cattle are a common source of food and are also used for labor in agriculture, such as plowing fields or pulling carts. In veterinary medicine, cattle are often referred to as "livestock" and may be treated for a variety of medical conditions, including diseases, injuries, and parasites. Some common medical issues that may affect cattle include respiratory infections, digestive problems, and musculoskeletal disorders. Cattle may also be used in medical research, particularly in the fields of genetics and agriculture. For example, scientists may study the genetics of cattle to develop new breeds with desirable traits, such as increased milk production or resistance to disease.

Isoproterenol is a synthetic beta-adrenergic agonist that is used in the medical field as a medication. It is a drug that mimics the effects of adrenaline (epinephrine) and can be used to treat a variety of conditions, including asthma, heart failure, and bradycardia (a slow heart rate). Isoproterenol works by binding to beta-adrenergic receptors on the surface of cells, which triggers a cascade of events that can lead to increased heart rate, relaxation of smooth muscle, and dilation of blood vessels. This can help to improve blood flow and oxygen delivery to the body's tissues, and can also help to reduce inflammation and bronchoconstriction (narrowing of the airways). Isoproterenol is available in a variety of forms, including tablets, inhalers, and intravenous solutions. It is typically administered as a short-acting medication, although longer-acting formulations are also available. Side effects of isoproterenol can include tremors, palpitations, and increased heart rate, and the drug may interact with other medications that affect the heart or blood vessels.

Xanthines are a group of compounds that include caffeine, theophylline, and theobromine. They are naturally occurring alkaloids found in plants such as coffee, tea, and cocoa. In the medical field, xanthines are used as bronchodilators to treat conditions such as asthma and chronic obstructive pulmonary disease (COPD). They work by relaxing the muscles in the airways, allowing air to flow more easily. Xanthines can also be used to treat heart rhythm disorders and to prevent blood clots. However, they can have side effects such as nausea, vomiting, and increased heart rate, and may interact with other medications.

In the medical field, binding sites refer to specific locations on the surface of a protein molecule where a ligand (a molecule that binds to the protein) can attach. These binding sites are often formed by a specific arrangement of amino acids within the protein, and they are critical for the protein's function. Binding sites can be found on a wide range of proteins, including enzymes, receptors, and transporters. When a ligand binds to a protein's binding site, it can cause a conformational change in the protein, which can alter its activity or function. For example, a hormone may bind to a receptor protein, triggering a signaling cascade that leads to a specific cellular response. Understanding the structure and function of binding sites is important in many areas of medicine, including drug discovery and development, as well as the study of diseases caused by mutations in proteins that affect their binding sites. By targeting specific binding sites on proteins, researchers can develop drugs that modulate protein activity and potentially treat a wide range of diseases.

In the medical field, a catalytic domain is a region of a protein that is responsible for catalyzing a specific chemical reaction. Catalytic domains are often found in enzymes, which are proteins that speed up chemical reactions in the body. These domains are typically composed of a specific sequence of amino acids that form a three-dimensional structure that allows them to bind to specific substrates and catalyze their breakdown or synthesis. Catalytic domains are important for many biological processes, including metabolism, signal transduction, and gene expression. They are also the target of many drugs, which can be designed to interfere with the activity of specific catalytic domains in order to treat diseases.

Vinca alkaloids are a group of naturally occurring compounds derived from the Madagascar periwinkle plant (Vinca rosea). They are used in the treatment of various types of cancer, including leukemia, lymphoma, and solid tumors such as breast, ovarian, and lung cancer. Vinca alkaloids work by binding to microtubules, which are essential components of the cell's cytoskeleton. By binding to microtubules, vinca alkaloids prevent the formation of new microtubules and stabilize existing ones, leading to cell death. The most commonly used vinca alkaloids in cancer treatment are vinblastine and vincristine. These drugs are typically administered intravenously and can cause a range of side effects, including nausea, vomiting, hair loss, and peripheral neuropathy (numbness or tingling in the hands and feet). However, they are often effective in controlling the growth of cancer cells and can be used in combination with other chemotherapy drugs to improve treatment outcomes.

In the medical field, cyclic P-oxides refer to a class of organic compounds that contain a ring of atoms with a double bond between two oxygen atoms and a single bond between one of the oxygen atoms and a phosphorus atom. These compounds are also known as phosphorus oxides or phosphorus ylides. Cyclic P-oxides are often used as intermediates in organic synthesis reactions, particularly in the synthesis of heterocyclic compounds such as pyrroles, furans, and thiophenes. They can also be used as reagents in organic reactions, such as in the Staudinger reduction, which is a method for converting aldehydes and ketones into primary amines. In addition to their use in organic synthesis, cyclic P-oxides have also been studied for their potential medicinal applications. For example, some cyclic P-oxides have been shown to have antitumor activity, and they are being investigated as potential treatments for cancer. Other cyclic P-oxides have been studied for their potential to treat neurological disorders, such as Alzheimer's disease and Parkinson's disease.

Nov 2003). "Structural evidence that brain cyclic nucleotide phosphodiesterase is a member of the 2H phosphodiesterase ... selectively activates the calcium-calmodulin sensitive isoform of cyclic nucleotide phosphodiesterase from human myometrium". ... "Purification to homogeneity and general properties of a novel phosphodiesterase hydrolyzing cyclic CMP and cyclic AMP". The ... "A homogeneous cyclic CMP phosphodiesterase hydrolyzes both pyrimidine and purine cyclic 2':3'- and 3':5'-nucleotides". The ...
... cyclic nucleotide phosphodiesterase:3'-nucleotidase. This enzyme participates in purine metabolism and pyrimidine metabolism. ... Anraku Y (1964). "A new cyclic phosphodiesterase having a 3′-nucleotidase activity from Escherichia coli B. I. purification and ... Anraku Y (1964). "A new cyclic phosphodiesterase having a 3′-nucleotidase activity from Escherichia coli B. II. Further studies ... Center MS, Behal FJ (1968). "A cyclic phosphodiesterase with 3′-nucleotidase activity from Proteus mirabilis". J. Biol. Chem. ...
"Biologic regulation through opposing influences of cyclic GMP and cyclic AMP: the Yin Yang hypothesis". Adv Cyclic Nucleotide ... June 1997). "cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes ... Bender AT, Beavo JA (September 2006). "Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use". Pharmacol. ... cyclic nucleotide phosphodiesterase (PDE2) on guinea pig left atria in eu- and hyperthyroidism" (PDF). Gen Physiol Biophys. 22 ...
Johner A, Kunz S, Linder M, Shakur Y, Seebeck T (March 2006). "Cyclic nucleotide specific phosphodiesterases of Leishmania ... "Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei". Biochimica et ... cyclic-AMP phosphodiesterase (EC 3.1.4.53, cAMP-specific phosphodiesterase, cAMP-specific PDE, PDE1, PDE2A, PDE2B, PDE4, PDE7, ... cyclic-AMP+phosphodiesterase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Portal: Biology (Articles ...
Essayan DM (November 2001). "Cyclic nucleotide phosphodiesterases". The Journal of Allergy and Clinical Immunology. 108 (5): ... Paraxanthine is a selective inhibitor of cGMP-preferring phosphodiesterase (PDE9) activity and is hypothesized to increase ... Paraxanthine is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits ... Paraxanthine is a phosphodiesterase type 9 (PDE9) inhibitor and it is sold as a research molecule for this same purpose. ...
Numerous cyclic nucleotide phosphodiesterases (PDE) can degrade cGMP by hydrolyzing cGMP into 5'-GMP. PDE 5, -6 and -9 are cGMP ... Cyclic guanosine monophosphate (cGMP) is a cyclic nucleotide derived from guanosine triphosphate (GTP). cGMP acts as a second ... cyclic monophosphate (8-Br-cGMP) Francis SH, Corbin JD (August 1999). "Cyclic nucleotide-dependent protein kinases: ... Brown RL, Strassmaier T, Brady JD, Karpen JW (2006). "The pharmacology of cyclic nucleotide-gated channels: emerging from the ...
cAMP's role in this process terminates upon hydrolysis to AMP by phosphodiesterase. Cyclic nucleotides are well-suited to act ... The two most well-studied cyclic nucleotides are cyclic AMP (cAMP) and cyclic GMP (cGMP), while cyclic CMP (cCMP) and cyclic ... A cyclic nucleotide (cNMP) is a single-phosphate nucleotide with a cyclic bond arrangement between the sugar and phosphate ... Finally, cyclic nucleotides can be distinguished from non-cyclic nucleotides because they are smaller and less polar. The ...
"Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine ... adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes". Molecular Pharmacology. 48 (1): 121-30 ... which also acts as a phosphodiesterase inhibitor that selectively inhibits phosphodiesterase type 2 (PDE2). "Sigma Aldrich". ... EHNA (erythro-9-(2-hydroxy-3-nonly)adenine) is a potent adenosine deaminase inhibitor, ...
Cyclic nucleotide 3'-phosphodiesterase: a membrane-bound, microtubule-associated protein and membrane anchor for tubulin". ... 3 (10): 1738-1739, 1742. doi:10.1128/mcb.3.10.1738. PMC 370035. PMID 6646120. Mill, F. D.; Naus, C. C.; Durand, M.; Bloom, F. E ... 3.0.CO;2-L. PMID 9722999. Oakley BR (December 2000). "An abundance of tubulins". Trends in Cell Biology. 10 (12): 537-42. doi: ... 105 (6 Pt 2): 3065-73. doi:10.1083/jcb.105.6.3065. PMC 2114727. PMID 3693406. Cowan NJ, Dobner PR, Fuchs EV, Cleveland DW ( ...
Lefièvre L, de Lamirande E, Gagnon C (2003). "Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable ... cyclic nucleotide phosphodiesterase 1A is an enzyme that in humans is encoded by the PDE1A gene. GRCh38: Ensembl release 89: ... cyclic nucleotide phosphodiesterases". J Biol Chem. 271 (2): 796-806. doi:10.1074/jbc.271.2.796. PMID 8557689. Michibata H, ... "Entrez Gene: PDE1A phosphodiesterase 1A, calmodulin-dependent". Bonaldo MF, Lennon G, Soares MB (1997). "Normalization and ...
2007). "Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes". J. Biol. Chem. 282 (45): 32749-57. doi:10.1074/ ... Rybalkin SD, Rybalkina I, Beavo JA, Bornfeldt KE (2002). "Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth ... cyclic nucleotide phosphodiesterase 1C is an enzyme that in humans is encoded by the PDE1C gene. GRCh38: Ensembl release 89: ... cyclic nucleotide phosphodiesterases". J Biol Chem. 271 (2): 796-806. doi:10.1074/jbc.271.2.796. PMID 8557689. "Entrez Gene: ...
... cyclic nucleotide 3'-phosphodiesterase, and myelin proteins in rat forebrain subfractions during development". Neurochem. Res. ... 119 (3): 421-7. doi:10.1093/oxfordjournals.jbchem.a021258. PMID 8830034. Tsuda M, Egashira M, Niikawa N, et al. (2000). "Cancer ... 264 (2): 1252-9. doi:10.1016/S0021-9258(19)85079-2. PMID 2562955. Fleischer B, Zambrano F (1973). "Localization of cerebroside- ... 52 (3): 951-8. doi:10.1016/0006-291X(73)91029-2. PMID 4710574. Farrell DF, McKhann GM (1971). "Characterization of cerebroside ...
"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling". ... Usually, phosphodiesterase refers to cyclic nucleotide phosphodiesterases, which have great clinical significance and are ... "Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase". Advances in Cyclic ... as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases ...
Fell, David A. (1980). "Theoretical analyses of the functioning of the high- and low-Km cyclic nucleotide phosphodiesterases in ... and low-Km cyclic nucleotide phosphodiesterases on the regulation of adenosine 3',5'-cyclic monophosphate (cAMP) From the early ... cyclic monophosphate in animal cells". Journal of Theoretical Biology. 84 (2): 361-385. doi:10.1016/s0022-5193(80)80011-7. ISSN ... El-Yassin, D I; Fell, D A; Lloyd, B B; Fisher, R B (1979). "The breakdown of 2,3-bis(phospho)-D-glycerate by Fe(III)- ...
... cyclic-nucleotide phosphodiesterase MeSH D08.811.277.352.640.160 - 2',3'-cyclic-nucleotide phosphodiesterases MeSH D08.811. ... cyclic nucleotide-regulated protein kinases MeSH D08.811.913.696.620.682.700.150.125 - cyclic amp-dependent protein kinases ... cyclic-GMP phosphodiesterase MeSH D08.811.277.352.640.150 - 3',5'- ... cyclic gmp-dependent protein kinases MeSH D08.811.913.696.620.682.700.150.575 - protamine kinase MeSH D08.811.913.696.620.682. ...
... cyclic nucleotide phosphodiesterases". J. Biol. Chem. 271 (2): 796-806. doi:10.1074/jbc.271.2.796. PMID 8557689. Aizawa Y, ... 2001). "Human Ca2+/calmodulin-dependent phosphodiesterase PDE1A: novel splice variants, their specific expression, genomic ... 60 Suppl 3 (Suppl 3): iii18-24. doi:10.1136/ard.60.90003.iii18. PMC 1766679. PMID 11890646. Loughney K, Martins TJ, Harris EA, ... 1517 (2): 278-87. doi:10.1016/s0167-4781(00)00293-1. PMID 11342109. Paulukat J, Bosmann M, Nold M, et al. (2001). "Expression ...
"Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase". The Journal ... "Myomegalin is a novel protein of the golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase". The Journal ... Zhang HT (2009). "Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs". Current ... Némoz G, Zhang R, Sette C, Conti M (Apr 1996). "Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene ...
Cyclic-nucleotide 3'-phosphodiesterase, a myelin-associated enzyme that makes up 4% of total CNS myelin protein Chronic ... a proposed class of living organisms smaller than the accepted lower limit size for life 2',3'- ...
Cyclic-nucleotide 3'-phosphodiesterase. Moreover, oligodendrocytes also developed and migrated into fiber bundles in mice when ... 560 (1-3): 192-8. doi:10.1016/S0014-5793(04)00086-9. PMID 14988021. Tan, Y; Xie, Z; Ding, M; Wang, Z; Yu, Q; Meng, L; Zhu, H; ... 137 (2): 740-5. PMC 218351. PMID 370098. van der Heyden, MA; Defize, LH (2003-05-01). "Twenty one years of P19 cells: what an ... 3 (12): 2271-9. doi:10.1128/mcb.3.12.2271. PMC 370098. PMID 6656766. McBurney, MW; Reuhl, KR; Ally, AI; Nasipuri, S; Bell, JC; ...
Cyclic-nucleotide 3'-phosphodiesterase (CNPase) List of distinct cell types in the adult human body List of human cell types ... 115 (2): 535-51. doi:10.1242/dev.115.2.535. PMID 1425339. Yokoo H, Nobusawa S, Takebayashi H, Ikenaka K, Isoda K, Kamiya M, ... 5 (3): 180-9. doi:10.1016/s1071-9091(98)80033-8. PMID 9777676. Káradóttir et al., 2007 Tkachev D, Mimmack ML, Ryan MM, et al. ( ... 81 (2): 871-927. doi:10.1152/physrev.2001.81.2.871. ISSN 0031-9333. PMID 11274346. Richardson, WD; Kessaris, N; Pringle, N (Jan ...
... cyclic-nucleotide phosphodiesterase EC 3.1.4.18: Now EC 3.1.16.1, spleen exonuclease EC 3.1.4.19: Now EC 3.1.13.3, ... phosphodiesterase * EC 3.1.4.59: cyclic-di-AMP phosphodiesterase * EC 3.1.4.60: pApA phosphodiesterase * EC 3.1.4.61: cyclic 2, ... glucose-1-phospho-D-mannosylglycoprotein phosphodiesterase EC 3.1.4.52: cyclic-guanylate-specific phosphodiesterase EC 3.1.4.53 ... cyclic-GMP phosphodiesterase EC 3.1.4.36: Now with EC 3.1.4.43 EC 3.1.4.37: 2′,3′-cyclic-nucleotide 3'-phosphodiesterase EC 3.1 ...
... cyclic-nucleotide 3'-phosphodiesterase and multiple molecules of the immune system. GRCh38: Ensembl release 89: ENSG00000197971 ... 3 (3): 96-9. doi:10.4024/18SH03R.jbpc.03.03. Media related to Myelin basic proteins at Wikimedia Commons Overview of all the ... 53 (2): 189-197. doi:10.1002/ana.10425. PMID 12557285. S2CID 43317994. Namer IJ, Steibel J, Poulet P, Armspach JP, Mohr M, ... The Golli mRNAs contain 3 exons unique to Golli-MBP, spliced in-frame to 1 or more MBP exons. They encode hybrid proteins that ...
... nucleotide phosphodiesterases". Biochemical Pharmacology. 21 (18): 2443-50. doi:10.1016/0006-2952(72)90414-5. PMID 4345859. ... a potent new inhibitor of cyclic 3',5'- ... and as a phosphodiesterase inhibitor selective for the PDE4 ... and characterization of human cAMP-specific phosphodiesterase (PDE4) subtypes A, B, C, and D". Biochemical and Biophysical ... ISBN 3-540-66127-1. Progress in Drug Research / Volume 31 (Progress in Drug Research). Boston: Birkhauser. 1987. p. 526. ISBN 3 ...
"Differential regulation of bovine brain calmodulin dependent cyclic nucleotide phosphodiesterase isozyme by cyclic AMP- ... Sharma, RK; Wirch, E; Wang, JH (May 25, 1978). "Inhibition of Ca2+-activated cyclic nucleotide phosphodiesterase reaction by a ... "Mechanism of activation of cyclic nucleotide phosphodiesterase: requirement of the binding of four Ca2+ to calmodulin for ... "Demonstration of bovine brain calmodulin dependent cyclic nucleotide phosphodiesterase isozymes by monoclonal antibodies". J ...
... cyclic nucleotide phosphodiesterase". Gene. 191 (1): 89-95. doi:10.1016/S0378-1119(97)00046-2. PMID 9210593. "Entrez Gene: ... Sadhu K, Hensley K, Florio VA, Wolda SL (1999). "Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A ... cyclic phosphodiesterase is an enzyme that in humans is encoded by the PDE2A gene. GRCh38: Ensembl release 89: ENSG00000186642 ... PDE2A phosphodiesterase 2A, cGMP-stimulated". Witzenrath M, Gutbier B, Schmeck B, et al. (2005). "Phosphodiesterase 2 ...
... phosphate phosphatase activities and cyclic nucleotide phosphodiesterase.[citation needed] The order Nidovirales can be divided ... Nidoviruses are named for the Latin nidus, meaning nest, as all viruses in this order produce a 3' co-terminal nested set of ... The structural proteins are encoded at the 3' region of the genome and are expressed from a set of subgenomic mRNAs.[citation ... Gulyaeva, Anastasia A.; Gorbalenya, Alexander E. (January 2021). "A nidovirus perspective on SARS-CoV-2". Biochemical and ...
Modulates the activity of membrane-bound enzymes: phosphodiesterase, cyclic nucleotides, adenylate cyclase, aldoreductase, ... Emoxypine (2-ethyl-6-methyl-3-hydroxypyridine), also known as Mexidol or Mexifin when used as the succinate salt, is an ... 3: 100121. doi:10.1016/j.crphar.2022.100121. PMC 9389226. PMID 35992374. Dumayev KM, Voronina TA, Smirnov LD (1995). ... Gruber W (1953). "Synthesis of 3-Hydroxy-2-alkylpyridines". Canadian Journal of Chemistry. 31 (6): 564-568. doi:10.1139/v53-079 ...
September 2003). "Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system ... Lugnier C (March 2006). "Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific ... WO 03012030, Movsesian M, "Isoform-Selective Inhibitors and Activators of PDE3 Cyclic Nucleotide Phosphodiesterases", published ... Oocyte maturation inhibitor Bender AT, Beavo JA (September 2006). "Cyclic nucleotide phosphodiesterases: molecular regulation ...
Yuasa K, Ohgaru T, Asahina M, Omori K (2001). "Identification of rat cyclic nucleotide phosphodiesterase 11A (PDE11A): ... Beavo JA, Conti M, Heaslip RJ (1994). "Multiple cyclic nucleotide phosphodiesterases". Mol. Pharmacol. 46 (3): 399-405. PMID ... cyclic nucleotide phosphodiesterase 11A: localization in human tissues". Int. J. Impot. Res. 17 (4): 320-5. doi:10.1038/sj.ijir ... cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cGMP to the corresponding 5'-monophosphates and ...
Compared with caffeine, theobromine is weaker in both its inhibition of cyclic nucleotide phosphodiesterases and its antagonism ... Essayan DM (November 2001). "Cyclic nucleotide phosphodiesterases". The Journal of Allergy and Clinical Immunology. 108 (5): ... The potential phosphodiesterase inhibitory effect of theobromine is seen only at amounts much higher than what people normally ... Its effect as a phosphodiesterase inhibitor is thought to be small. Theobromine has no significant stimulant effect on the ...
Cyclic nucleotide PhosphoDiesterase 1 Comparative Info. Sequence Details Sequence The S. cerevisiae Reference Genome sequence ... Cyclic nucleotide phosphodiesterase; hydrolyzes ADP-ribose 1, 2-cyclic phosphate to ADP-ribose 1-phosphate; may have a ... Cyclic nucleotide phosphodiesterase that hydrolyzes nucleoside 2,3 cyclic phosphodiester bond to yield nucleoside 2- ...
Francis, S.H., Sekhar, K.R., Ke, H. and Corbin, J.D. (2011) Inhibition of Cyclic Nucleotide Phosphodiesterases by ... The interaction with the non-selective PDE (cyclic nucleotide phosphodiesterase) inhibitor 3-isobutyl-1-methylxanthine (IBMX) ... Chen, Z.S., Lee, K. and Kruh, G.D. (2001) Transport of Cyclic Nucleotides and Estradiol 17-Beta-d-glucuronide by Multidrug ... Schultz, C., Vaskinn, S., Kildalsen, H. and Sager, G. (1998) Cyclic AMP Stimulates the Cyclic GMP Egression Pump in Human ...
... cyclic nucleotide phosphodiesterase 1B(Homo sapiens (Human)). Plexxikon. Ligand. BDBM14390(5-[2-ethoxy-5-(4-methyl-1- ... cyclic nucleotide phosphodiesterase 1A/1B(Bos taurus). Bayer AG. Curated by ChEMBL. ... cyclic nucleotide phosphodiesterase 1A/1B(Bos taurus). Bayer AG. Curated by ChEMBL. ... cyclic nucleotide phosphodiesterase 1B/Dual specificity calcium/calmodulin-dependent 3,5-cyclic nucleotide phosphodiesterase ...
Cilostazol is an antiplatelet that selectively inhibits cyclic nucleotide phosphodiesterase type 3 (PDE III) [13] and is ... 1,2Italo Porto. ,1,2,3Antonella Gallo. ,1,2Claudia Camaioni. ,1,2Roberta Della Bona. ,1,2Antonio Grieco. ,1,2Filippo Crea. ,1,2 ... thus increasing the cyclic AMP (cAMP) content of human platelets. Additionally, cilostazol has another important ... 2. Case Report. A 65-year old Caucasian male was admitted to the Department of Internal Medicine of our Hospital for the sudden ...
... cyclic-nucleotide 3′-phosphodiesterase (CNP) and MBP indicates the degree of OL differentiation in the cultures, as these are ... Data represent the mean ± SEM (n = 3-4). *p , 0.05; **p , 0.01 (E, I, Students t test; G, K, two-way ANOVA with Bonferroni ... 4B). At DIV3, MAG+ve Ilk−/− OLs were predominantly Stage 1, whereas MAG+ve Ilkfl/fl OLs were largely Stage 3 (Fig. 4C). At DIV6 ... 2A,B). Accordingly, fewer Ilk−/− OLs expressed MAG or MBP as compared to wild-type (Ilkfl/fl) cells. However, a certain ...
... phosphodiesterase-5 (IC 50 =539.72 µg/mL); arginase (41.53 µg/mL)] than CG [phosphodiesterase-5 (IC 50 =611.35 µg/mL); arginase ... Also, both extracts inhibited phosphodiesterase-5 and arginase in a dose-dependent manner in vitro ; nevertheless, HU showed ... arginase and phosphodiesterase-5) and type-2 diabetes (α-amylase and α-glucosidase) were determined. Antioxidant properties of ... Conclusions The ability of samples extract to inhibit some of key enzymes relevant to erectile dysfunction and type-2 diabetes ...
Cyclic-Nucleotide Phosphodiesterases 2,3-Didehydro-3-deoxythymidine use Stavudine 2,3-Dideoxy-3-thiacytidine use ... 2-Fluoro-2-deoxyglucose use Fluorodeoxyglucose F18 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10- ... 2-Amino-5-phosphonovaleric Acid use 2-Amino-5-phosphonovalerate 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone use ... 3-Deoxyarabinoheptulosonate-7-Phosphate Synthetase use 3-Deoxy-7-Phosphoheptulonate Synthase 3 End Processing, RNA use RNA 3 ...
Cyclic-Nucleotide Phosphodiesterases 2,3-Didehydro-3-deoxythymidine use Stavudine 2,3-Dideoxy-3-thiacytidine use ... 2-Amino-5-phosphonovaleric Acid use 2-Amino-5-phosphonovalerate 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone use ... 2-Dehydro-3-Deoxyphosphoheptonate Aldolase use 3-Deoxy-7-Phosphoheptulonate Synthase 2-Fluoro-2-deoxy-D-glucose use ... 2,6-Dichlorophenolindophenol use 2,6-Dichloroindophenol 3 beta-Hydroxy-delta-5-Steroid Dehydrogenase use Progesterone Reductase ...
Cyclic-Nucleotide Phosphodiesterases 2,3-Didehydro-3-deoxythymidine use Stavudine 2,3-Dideoxy-3-thiacytidine use ... 2-Fluoro-2-deoxyglucose use Fluorodeoxyglucose F18 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10- ... 2-Amino-5-phosphonovaleric Acid use 2-Amino-5-phosphonovalerate 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone use ... 3-Deoxyarabinoheptulosonate-7-Phosphate Synthetase use 3-Deoxy-7-Phosphoheptulonate Synthase 3 End Processing, RNA use RNA 3 ...
Cyclic-Nucleotide Phosphodiesterase use 3,5-Cyclic-AMP Phosphodiesterases. 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) ... 3-Keto-5-alpha-Steroid delta-4-Dehydrogenase use Testosterone 5-alpha-Reductase ... 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester ... 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ...
Cyclic-Nucleotide Phosphodiesterases 2,3-Didehydro-3-deoxythymidine use Stavudine 2,3-Dideoxy-3-thiacytidine use ... 2-Fluoro-2-deoxyglucose use Fluorodeoxyglucose F18 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10- ... 2-Amino-5-phosphonovaleric Acid use 2-Amino-5-phosphonovalerate 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone use ... 3-Deoxyarabinoheptulosonate-7-Phosphate Synthetase use 3-Deoxy-7-Phosphoheptulonate Synthase 3 End Processing, RNA use RNA 3 ...
Cyclic-Nucleotide Phosphodiesterases 2,3-Didehydro-3-deoxythymidine use Stavudine 2,3-Dideoxy-3-thiacytidine use ... 2-Amino-5-phosphonovaleric Acid use 2-Amino-5-phosphonovalerate 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone use ... 2-Dehydro-3-Deoxyphosphoheptonate Aldolase use 3-Deoxy-7-Phosphoheptulonate Synthase 2-Fluoro-2-deoxy-D-Glucose use ... 2,6-Dichlorophenolindophenol use 2,6-Dichloroindophenol 3 beta-Hydroxy-delta-5-Steroid Dehydrogenase use Progesterone Reductase ...
Cyclic-Nucleotide Phosphodiesterases 2,3-Didehydro-3-deoxythymidine use Stavudine 2,3-Dideoxy-3-thiacytidine use ... 2-Amino-5-phosphonovaleric Acid use 2-Amino-5-phosphonovalerate 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone use ... 2-Dehydro-3-Deoxyphosphoheptonate Aldolase use 3-Deoxy-7-Phosphoheptulonate Synthase 2-Fluoro-2-deoxy-D-Glucose use ... 2,6-Dichlorophenolindophenol use 2,6-Dichloroindophenol 3 beta-Hydroxy-delta-5-Steroid Dehydrogenase use Progesterone Reductase ...
Cyclic-Nucleotide Phosphodiesterase use 3,5-Cyclic-AMP Phosphodiesterases. 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) ... 3-Keto-5-alpha-Steroid delta-4-Dehydrogenase use Testosterone 5-alpha-Reductase ... 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester ... 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ...
Cyclic-Nucleotide Phosphodiesterase use 3,5-Cyclic-AMP Phosphodiesterases. 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific) ... 3-Keto-5-alpha-Steroid delta-4-Dehydrogenase use Testosterone 5-alpha-Reductase ... 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester ... 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer ...
Cyclic-Nucleotide Phosphodiesterases 2,3-Didehydro-3-deoxythymidine use Stavudine 2,3-Dideoxy-3-thiacytidine use ... 2-Amino-5-phosphonovaleric Acid use 2-Amino-5-phosphonovalerate 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone use ... 2-Dehydro-3-Deoxyphosphoheptonate Aldolase use 3-Deoxy-7-Phosphoheptulonate Synthase 2-Fluoro-2-deoxy-D-glucose use ... 2,6-Dichlorophenolindophenol use 2,6-Dichloroindophenol 3 beta-Hydroxy-delta-5-Steroid Dehydrogenase use Progesterone Reductase ...
This is probably an artifactual activity; recall that the biologically active cyclic nucleotides are those with a 3′:5′ ... phosphodiesterase. There are many higher molecular weight proteins present in the gel-electrophoretic pattern of myelin. These ... cyclic nucleotide-3′-phosphodiesterase (CNP), which comprises several percent of myelin protein [23]. Although there are low ... cyclic cytidine monophosphate (cCMP) and cyclic uridine monophosphate (cUMP) analogs, all of which are hydrolyzed to the ...
The lowest effective dose, 3 mg/kg, was able to improve anxiety and spatial learning deficits in this model of ... Cyclic-nucleotide 3-phosphodiesterase. CysLTs:. Cysteinyl leukotrienes. CysLTR:. Cysteinyl leukotriene receptor. d:. Diffusion ... 3B, D). The average MD in the cortex of saline-treated animals was 3.9 × 10-4 ± 0.01 × 10-4 mm2/s, which increased to 4.1 × 10- ... 2C). In contrast to the findings in the cortex, no significant alteration in the number of PV+ interneurons was found in the ...
The ability of methylxanthines to inhibit cyclic nucleotide phosphodiesterases is often cited to explain their therapeutic ... Thus, phosphodiesterase inhibition is probably not important to the therapeutic effects of methylxanthines. ... Plasma caffeine concentrations that raise blood pressure are below the threshold for phosphodiesterase inhibition. ... 2] However, caffeine was considered in one study as a potential drug of abuse and has even been described as a model drug of ...
... cyclic nucleotide 3′-phosphodiesterase (Cnp) in humans and mice causes white matter inflammation and catatonic signs. These ... 1 treatment alone, 2) the correlation of catatonic signs and executive dysfunction, 3) the phenotype of leftover microglia ... Importantly, 2 extended rounds of CSF1R inhibition are not superior to 1 treatment regarding any readout investigated (magnetic ... Here we address for the first time preclinical topics crucial for translation, most importantly 1) the comparison of 2 long- ...
Inotropic response as multiple process can be induced by inhibition of phosphodiesterase, accumulation of cyclic nucleotides ... Influence of metabolism modifiers of cyclic nucleotides on contractility of right ventricle of rat heart with intact and ... OBJECTIVE: We investigated the roles of theophylline, nonspecific phosphodiesterase inhibitor, and imidazole, an activator of ... occur via cyclic guanosine monophosphate. The synthesized nitric oxide exhibits its effect in the cells where it is produced, ...
... cyclic nucleotide 3 phosphodiesterase CNP1 ... ADP-ribosylation factor guanine nucleotide-exchange factor 2 ( ... 68.109884 68.255912 ADP-ribosylation factor guanine nucleotide-exchange factor 1 (brefeldin A-inhibited) ARFGEP1; BIG1; P200 ... the data is rescaled to a mean of 8 units with a standard deviation of 2 units (what we call 2Z + 8 normalized data). Usage ... member C1 2-ALPHA-HSD; 20-ALPHA-HSD; C9; DD1; DD1/DD2; DDH; DDH1; H-37; HAKRC; HBAB; MBAB ...
D3.633.100.759.646.454.160 Cyclic IMP D3.438.759.646.616.300 D3.633.100.759.646.616.300 Cyclic Nucleotide-Gated Cation Channels ... Phosphodiesterase D12.776.641.580.124 D12.776.631.580.124 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine D3.438. ... Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels D12.776.543.550.425.476 D12.776.543.550.450.476 Hypogravity G1.595 ... Cyclic ADP-Ribose D3.438.759.646.138.124.70.125.195 D3.633.100.759.646.138.124.70.125.195 Cyclic AMP D3.438.759.646.138.395 ...
D3.633.100.759.646.454.160 Cyclic IMP D3.438.759.646.616.300 D3.633.100.759.646.616.300 Cyclic Nucleotide-Gated Cation Channels ... Phosphodiesterase D12.776.641.580.124 D12.776.631.580.124 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine D3.438. ... Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels D12.776.543.550.425.476 D12.776.543.550.450.476 Hypogravity G1.595 ... Cyclic ADP-Ribose D3.438.759.646.138.124.70.125.195 D3.633.100.759.646.138.124.70.125.195 Cyclic AMP D3.438.759.646.138.395 ...
... cyclic-nucleotide phosphodiesterase (UMP) (periplasm). EcolC_3793. 23PDE4pp. 2,3-cyclic-nucleotide phosphodiesterase (CMP) ( ...
Cyclic AMP / metabolism* * Cyclic Nucleotide Phosphodiesterases, Type 3 / chemistry * Cyclic Nucleotide Phosphodiesterases, ... cyclic AMP (cAMP), by altering the activity of the cAMP-degrading phosphodiesterase PDE3B. Biochemical studies of the copper- ... Copper regulates cyclic-AMP-dependent lipolysis Nat Chem Biol. 2016 Aug;12(8):586-92. doi: 10.1038/nchembio.2098. Epub 2016 Jun ... Lakshmi Krishnamoorthy 1 2 , Joseph A Cotruvo Jr 1 , Jefferson Chan 1 , Harini Kaluarachchi 1 , Abigael Muchenditsi 3 , Venkata ...
Phosphodiesterases listed: PDE, PLC, PLD. [1] Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases ... They are essential regulators of cyclic nucleotide signaling with diverse physiological functions. Roughly, the sub-types can ... Potent phosphodiesterase inhibitor and an aldehyde oxidase (AO) substrate €90.00 3169 Crisaborole Potent PDE4 inhibitor; Anti- ... No less than eleven sub-types of the enzyme family of phosphodiesterases (PDE; EC 3.1.4.-) are known to date, many of which ...
... cyclic nucleotide phosphodiesterases, proteases, nitric oxide synthases, small G proteins related to Ras, membrane receptors, ... This generates reduced pyridine nucleotides required for biosynthetic reactions (Fig. Groh G, Simoni M, Rolla P, Rockwood C. ... Nat Rev Genet 3:662673. 3) lim [k12 sin1(k12re)] re 6. Fx edge trading system 2. The peritoneum of the Pfannenstiel incision is ... Step 3: Pre-production and practice The easiest way to fail with online video training is to have your SME show up the day of ...
Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther. 1991; 51: 13-3. ... Cyclic GMP: synthesis, metabolism, and function. In Advances in Pharmacology, ed. Murad P. New York: Academic Press. 1994; 115- ... 2008; 24(3): 379-381. Mahawong P, Srisuwan T Idiopathic high-flow priapism in a pediatric patient. J Pediatr Urol. 2011; 7(1): ... 2007; 70(3): 590 e3-e5 Sandler G, Chennapragada SM, Soundappan SS. Pediatric high-flow priapism and super-selective angiography ...
  • A corresponding effect was observed after addition of 1000 μM cGMP and 1000 μM IBMX for 3 days. (scirp.org)
  • Our research interests are in the field of cyclic nucleotide signaling and cardiovascular biology, with a particular focus on cyclic nucleotide phosphodiesterases (PDEs) that catalyze the hydrolysis of cyclic nucleotide second messengers (cAMP and cGMP). (rochester.edu)
  • cAMP and cGMP regulate a wide variety of cardiac functions, from the short-term effects on myocyte contraction/ relaxation to long-term effects such as gene expression and structural remodeling ( Figure 2 ). (rochester.edu)
  • 7] Ghiadoni L, Versari D, Taddei S. Phosphodiesterase 5 inhibition in essential hypertension. (degruyter.com)
  • Here we address for the first time preclinical topics crucial for translation, most importantly 1) the comparison of 2 long-term PLX5622 applications (prevention and treatment) vs. 1 treatment alone, 2) the correlation of catatonic signs and executive dysfunction, 3) the phenotype of leftover microglia evading depletion, and 4) the role of intercellular interactions for efficient CSF1R inhibition. (mpg.de)
  • Importantly, 2 extended rounds of CSF1R inhibition are not superior to 1 treatment regarding any readout investigated (magnetic resonance imaging and magnetic resonance spectroscopy, behavior, immunohistochemistry). (mpg.de)
  • The interaction with the non-selective PDE (cyclic nucleotide phosphodiesterase) inhibitor 3-isobutyl-1-methylxanthine (IBMX) was tested after three days. (scirp.org)
  • We aimed to evaluate the effects of the phosphodiesterase 5 inhibitor sildenafil on CFR in diabetics with erectile dysfunction. (biomedcentral.com)
  • Clopidogrel exerts its antiplatelet effect by inhibiting the binding of adenosine diphosphate (ADP) to its receptor (P2Y12) and consequent ADP-mediated platelet activation [ 3 ]. (hindawi.com)
  • 2. Benau D., Szabo E.I., Terner C. Endogenous inhibitors of cyclic adenosine 3',5'-monophosphate-phosphodiesterase in rat epididymis. (abvpress.ru)
  • 3. Razzaboni B., Terner C. Cyclic adenosine 3',5'-monophosphate-phosphodiesterases in epididymis and prostate of castrate and of aged rats. (abvpress.ru)
  • Garg, U.C. and Hassid, A. (1989) Nitric Oxide-Generating Vasodilators and 8-Bromo-cyclic Guanosine Monophosphate Inhibit Mitogenesis and Proliferation of Cultured Rat Vascular Smooth Muscle Cells. (scirp.org)
  • Chen, Z.S., Lee, K. and Kruh, G.D. (2001) Transport of Cyclic Nucleotides and Estradiol 17-Beta-d-glucuronide by Multidrug Resistance Protein 4. (scirp.org)
  • Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. (urologi.or.id)
  • Reduced expression of 2′-3′-cyclic nucleotide 3′-phosphodiesterase (Cnp) in humans and mice causes white matter inflammation and catatonic signs. (mpg.de)
  • Figure 2: Representative picrosirius Red staining images of heart sections from mice subjected to sham (left) and transverse aortic constriction (TAC) (right). (rochester.edu)
  • Cardiac hypertrophy and arrhythmia in mice induced by a mutation in ryanodine receptor 2. (rochester.edu)
  • Evidence for androgen-dependent phosphodiesterase activity in rat seminal vesicle and epididymis. (abvpress.ru)
  • 7. Swinnen J.V., Joseph D.R., Conti M. Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. (abvpress.ru)
  • Blood tests revealed severe leukopenia (white cells 1 × 10 3 / μ L) with marked neutropenia (neutrophils 3%), anaemia (haemoglobin 9.9 g/dL), and an important rise in inflammatory markers (C-reactive protein 122 mg/dL). (hindawi.com)
  • 2] Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. (axonmedchem.com)
  • They are essential regulators of cyclic nucleotide signaling with diverse physiological functions. (axonmedchem.com)
  • We aim to reveal new molecular targets for pharmacologic modulation of specific cyclic nucleotide signaling in the treatment of cardiovascular diseases. (rochester.edu)
  • 1] Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. (axonmedchem.com)
  • Cyclic GMP was able to mimic the antiproliferative effect of SNP on HEK293 cells. (scirp.org)
  • Using a mouse model of genetic copper misregulation, in combination with pharmacological alterations in copper status and imaging studies in a 3T3-L1 white adipocyte model, we found that copper regulates lipolysis at the level of the second messenger, cyclic AMP (cAMP), by altering the activity of the cAMP-degrading phosphodiesterase PDE3B. (nih.gov)
  • This study was designed to investigate the effects of Hunteria umbellata (HU) seeds and Cylicodiscus gabunensis (CG) stem barks aqueous extracts on key enzymes relevant to erectile dysfunction (phosphodiesterase-5 and arginase) and type-2 diabetes (α-amylase and α-glucosidase). (degruyter.com)
  • In ascertaining the erectogenic and antidiabetic properties of the extracts, the effects of the extracts on activities of some enzymes relevant to erectile dysfunction (arginase and phosphodiesterase-5) and type-2 diabetes (α-amylase and α-glucosidase) were determined. (degruyter.com)
  • The ability of samples' extract to inhibit some of key enzymes relevant to erectile dysfunction and type-2 diabetes could render them cheap, natural and alternative therapy with erectogenic and antidiabetic potentials. (degruyter.com)
  • 6. Mewe M., Bauer C.K., Müller D., Middendorff R. Regulation of spontaneous contractile activity in the bovine epididymal duct by cyclic guanosine 5'-monophosphate-dependent pathways. (abvpress.ru)
  • Belongs to the cyclic nucleotide phosphodiesterase family. (string-db.org)
  • The versatility and specificity of cyclic nucleotide signaling is achieved through specific compartmentalization of different cyclic nucleotide pools that are controlled by distinct PDE isoforms. (rochester.edu)
  • Since chemicals that are structurally related can have distinct saliences for an organism [ 3 ], these cues must be identified and differentiated in order to elicit the appropriate behavior. (plos.org)
  • Proc Natl Acad Sci U S A. 2021 Aug 3;118(31):e2107898118. (rochester.edu)
  • Moreover, this dose is 5-10 times higher than the dose necessary to stimulate the caudate nucleus (extrapyramidal motor system) and the neural structures regulating the sleep-wake cycle, the 2 functions that are most sensitive to caffeine. (medscape.com)
  • The Protective Role of Natriuretic Peptide Receptor 2 against High Salt Injury in the Renal Papilla. (rochester.edu)
  • To understand the specific cyclic nucleotide signaling responsible for SMC phenotypic alteration, we have performed initial discovery screening for PDE isozymes that are differentially expressed in contractile versus synthetic SMCs. (rochester.edu)
  • METHODS: We recorded the P300 wave using an auditory oddball paradigm in 60 patients (mean age 51.1±6.2 years, range 40-62 years), with subclinical hypothyroidism (normal mean value of FT4, with elevated TSH levels) at baseline, after 3 months, after 6 months and in 30 healthy control subjects. (bvsalud.org)
  • Pilz, R.B. and Broderick, K.E. (2005) Role of Cyclic GMP in Gene Regulation. (scirp.org)
  • A Novel Role of Cyclic Nucleotide Phosphodiesterase 10A in Pathological Cardiac Remodeling and Dysfunction. (rochester.edu)
  • Dual antiplatelet therapy with aspirin plus clopidogrel has become the standard treatment of patients undergoing coronary stenting [ 1 , 2 ]. (hindawi.com)
  • In general, the array data that we enter in GeneNetwork have been log transformed and then z-score normalized, but instead of leaving the mean at 0 and the standard deviation of 1 unit, the data is rescaled to a mean of 8 units with a standard deviation of 2 units (what we call 2Z + 8 normalized data). (genenetwork.org)
  • Arterial blood gas levels (through an indwelling line [eg, umbilical arterial catheter or preductal peripheral arterial line]): To assess the pH, partial pressure of carbon dioxide (PaCO 2 ) and the partial pressure of oxygen (PaO 2 ) which might be higher in the preductal arterial line. (medscape.com)
  • Catalyzes the reduction of hydroxylamine to form NH(3) and H(2)O. (string-db.org)
  • 25 kg/m 2 and left ventricular hypertrophy exhibited the highest reduction of CFR after sildenafil. (biomedcentral.com)
  • Table A-1 and Table A-2 contain the name, location, forward and reverse primer for each SNP. (cdc.gov)
  • Animals continuously encounter heterogenous mixtures of chemicals that fluctuate in their concentrations and temporal properties, and provide information about the presence and location of food, mates, competitors, and predators [ 1 , 2 ]. (plos.org)
  • In the United States, the daily intake of caffeine from all sources is estimated to be 3 mg/kg/person, with two thirds of it coming from coffee consumed by subjects older than 10 years. (medscape.com)
  • Case(s) Report: A 7 years old boy presented with persistent and painless erections without sexual stimulation for 24 hours, the erection was first noticed when he woke up in the morning after accidentally consuming aphrodisiac chocolate 2 days before admitted to the hospital. (urologi.or.id)
  • clinical nutrition as a specialty goes here HN - 2008 BX - Nutrition FX - Diet FX - Food DH - Child Nutrition DI - 052504 MN - SP6.021.062 MS - Nutrition of children aged 2-10 years. (bvsalud.org)
  • We recorded the P300 wave using an auditory oddball paradigm in 60 consecutive brain infarct patients at baseline (i.e., within 4 weeks after the stroke), after 3 months, after 12 months and in 30 healthy control subjects. (bvsalud.org)
  • Also, the results of the P300 latency of patients with the left-sided lesions was significantly longer compared to the patients with right-sided lesions on the beginning of the study but not 3 and 12 months after the stroke. (bvsalud.org)
  • On follow-up after 2 months reported that patient had normal erections with no further episodes of priapism. (urologi.or.id)
  • [ 2 ] However, caffeine was considered in one study as a potential drug of abuse and has even been described as a model drug of abuse. (medscape.com)
  • After more than two millennia of study, this POSTULATE was found to be independent n ): il Xi 2 Ill2 - 2II2 of the others. (binaryoptioninc.com)